Form 4: ImageneBio Director Acquires Shares Post-Merger

ImageneBio Director Stephen Hui Wang reported the indirect acquisition of 250,721 common shares following the merger with Inmagene Biopharmaceuticals.

Summary

• Director Stephen Hui Wang indirectly acquired 250,721 shares of ImageneBio, Inc. common stock on July 25, 2025.
• This acquisition resulted from the merger between Ikena Oncology, Inc. (now ImageneBio, Inc.) and Inmagene Biopharmaceuticals, which closed on July 25, 2025.
• Each ordinary and preferred share of Legacy Inmagene was converted into 0.003051 shares of ImageneBio common stock.
• The shares were acquired through entities controlled by Mr. Wang: HLC Healthcare HK Limited (188,042 shares), Galaxy Alpha L.P. (50,144 shares), and Magic Hat L.P. (12,535 shares).

Sentiment

Score: 7

Explanation: The filing reflects the successful completion of a significant corporate event (merger) and a director's resulting indirect ownership, which is generally positive, though the late filing is a minor procedural negative.

Positives

• Completion of the merger between Ikena Oncology, Inc. and Inmagene Biopharmaceuticals, forming ImageneBio, Inc.
• Director Stephen Hui Wang now holds a significant indirect beneficial ownership of 250,721 common shares in the newly formed entity.

Negatives

• The Form 4 filing was submitted late due to delays in obtaining the reporting person's EDGAR codes.

Risks

• Mr. Wang disclaims beneficial ownership of the shares held by HLC Healthcare HK Limited, Galaxy Alpha L.P., and Magic Hat L.P., except to the extent of his pecuniary interest therein, if any.

Future Outlook

No explicit forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This announcement reflects the completion of a strategic merger within the biopharmaceutical industry, leading to the formation of ImageneBio, Inc. and the subsequent adjustment of insider ownership stakes.

Related Party Transactions

• Stephen Hui Wang, a Director and 10% owner, controls HLC Healthcare HK Limited, Galaxy Alpha L.P., and Magic Hat L.P. through HLC GP III Company Limited, which acted as the general partner for these entities in the share acquisition.

Stakeholder Impact

• Shareholders of ImageneBio now have a director with a significant indirect stake in the company following the merger.

Key Dates

Recommendation

This Form 4 primarily reports the indirect acquisition of shares by a director following a merger, which is an expected outcome of a previously announced corporate event. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate for existing investors awaiting further operational updates from the newly combined entity.

Keywords

ImageneBio, IMA, Stephen Hui Wang, Form 4, Insider Transaction, Merger, Share Acquisition, Inmagene Biopharmaceuticals, Director, Beneficial Ownership